{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T19:04:35Z","timestamp":1769886275936,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Radioactive iodine therapy (RAIT) is used to treat patients with thyroid cancer at high risk of recurrence or those with distant metastases. Small amounts of iodine-131 (I-131) are excreted in the stool after RAIT. Thyroid hormone withdrawal (THW) before RAIT can cause constipation, increasing radiation exposure to the colon. Although measuring colonic radiation using I-131 dosimetry would be challenging, colonic radiation dose can be estimated using I-131 whole-body scintigraphy post-RAIT. Therefore, we aimed to determine the clinical risk factors, including THW, associated with colonic distribution on I-131 scintigraphy post-RAIT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We analyzed 251 patients who received 530 RAITs, categorized into two groups based on the preparation method. We compared the relationship between clinical risk factors (including preparation method) and colonic I-131 distribution 3 d post-RAIT. In addition, we compared the frequency and degree of colonic I-131 distribution between patients who received RAITs with stimulant laxatives and those who received RAITs with osmotic laxatives. Four subgroup analyses were conducted based on the preparation method and defecation frequency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We performed 253 RAITs (47.7%) using recombinant human thyrotropin, while the remaining 277 RAITs (52.3%) were performed using THW. In the multivariate analysis, THW, higher RAIT dose (\u2265\u20093.7\u00a0GBq), and fewer defecation frequencies (\u2264\u20092 times) were significantly associated with a higher frequency of colonic I-131 distribution (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0206, 0.0020, and 0.0006, respectively). Of the patients treated using THW RAITs, which relieved constipation, those treated with RAITs with stimulant laxatives had significantly lower colonic I-131 distribution than did those treated with RAITs with osmotic laxatives (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0378).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>THW, high-dose RAIT, and defecation frequency were significantly associated with colonic I-131 distribution. Pre-treatment strategies, such as the use of stimulant laxatives should be considered to reduce colonic radiation exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11604-025-01882-7","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:11:43Z","timestamp":1759227103000},"page":"394-401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical factors affecting colonic iodine-131 distribution after radioactive iodine therapy for thyroid cancer"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-3134","authenticated-orcid":false,"given":"Noriko","family":"Takata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Itou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reia","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Takimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhito","family":"Kido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"1882_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1\u2013133.","journal-title":"Thyroid"},{"key":"1882_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/0146645314558019","volume":"44","author":"S Mattsson","year":"2015","unstructured":"Mattsson S, Johansson L, Leide Svegborn S, Liniecki J, No\u00dfke D, Riklund KA\u02da, et al. Radiation dose to patients from radiopharmaceuticals: a compendium of current information related to frequently used substances. Ann ICRP. 2015;44:7\u2013321.","journal-title":"Ann ICRP"},{"key":"1882_CR3","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1088\/1361-6498\/ac149a","volume":"41","author":"J Taprogge","year":"2021","unstructured":"Taprogge J, Carnegie-Peake L, Murray I, Gear JI, Flux GD. Adjustment of the iodine ICRP population pharmacokinetic model for the use in thyroid cancer patients after thyroidectomy. J Radiol Prot. 2021;41:1034\u201344.","journal-title":"J Radiol Prot"},{"key":"1882_CR4","doi-asserted-by":"publisher","first-page":"1389113","DOI":"10.3389\/fphys.2024.1389113","volume":"15","author":"G-M Xu","year":"2024","unstructured":"Xu G-M, Hu M-X, Li S-Y, Ran X, Zhang H, Ding X-F. Thyroid disorders and gastrointestinal dysmotility: an old association. Front Physiol. 2024;15:1389113.","journal-title":"Front Physiol"},{"key":"1882_CR5","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1056\/NEJMoa1109589","volume":"366","author":"U Mallick","year":"2012","unstructured":"Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366:1674\u201385.","journal-title":"N Engl J Med"},{"key":"1882_CR6","first-page":"277","volume":"40","author":"D Bartholomeusz","year":"1999","unstructured":"Bartholomeusz D, Chatterton BE, Bellen JC, Gaffney R, Hunter A. Segmental colonic transit after 67Ga-citrate in healthy subject and those with chronic idiopathic constipation. J Nucl Med. 1999;40:277\u201382.","journal-title":"J Nucl Med"},{"key":"1882_CR7","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1007\/s10620-024-08564-w","volume":"69","author":"A Ifrah","year":"2024","unstructured":"Ifrah A, Kanaparthi J, Fromer R, Gayner AH, Maurer AH, Dadparvar S, et al. Whole gut transit scintigraphy for the assessment of patients with symptoms of chronic constipation. Dig Dis Sci. 2024;69:3875\u201381.","journal-title":"Dig Dis Sci"},{"key":"1882_CR8","first-page":"985","volume":"31","author":"RG McLean","year":"1990","unstructured":"McLean RG, Smart RC, Gaston-Parry D, Barbagallo S, Baker J, Lyons NR, et al. Colon transit scintigraphy in health and constipation using oral iodine-131-cellulose. J Nucl Med. 1990;31:985\u20139.","journal-title":"J Nucl Med"},{"key":"1882_CR9","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1016\/j.mayocp.2019.01.031","volume":"94","author":"AE Bharucha","year":"2019","unstructured":"Bharucha AE, Wald A. Chronic constipation. Mayo Clin Proc. 2019;94:2340\u201357.","journal-title":"Mayo Clin Proc"},{"key":"1882_CR10","first-page":"930","volume":"2","author":"M Roque","year":"2015","unstructured":"Roque M, Bouras EP. Epidemiology and management of chronic constipation in elderly patients. Clin Interv Aging. 2015;2:930.","journal-title":"Clin Interv Aging"},{"key":"1882_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02159-9","author":"S Ikuta","year":"2024","unstructured":"Ikuta S, Saito Y, Takata S, Nakatani Y, Nagatomo I, Shiba S, et al. Variability in non-tumor areas of colorectal cancer patients as revealed by endoscopic intestinal step biopsies. Mol Cancer. 2024. https:\/\/doi.org\/10.1186\/s12943-024-02159-9.","journal-title":"Mol Cancer"},{"key":"1882_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.","journal-title":"N Engl J Med"},{"key":"1882_CR13","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s00259-017-3900-4","volume":"45","author":"TD Poeppel","year":"2018","unstructured":"Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, et al. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:824\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1882_CR14","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.2217\/fon.10.127","volume":"6","author":"R Rahbari","year":"2010","unstructured":"Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol. 2010;6:1771\u20139.","journal-title":"Future Oncol"},{"key":"1882_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ijrobp.2005.02.043","volume":"63","author":"C Bal","year":"2005","unstructured":"Bal C, Kumar A, Tripathi M, Chandrashekar N, Phom H, Murali NR, et al. High-dose radioiodine treatment for differentiated thyroid carcinoma is not associated with change in female fertility or any genetic risk to the offspring. Int J Radiat Oncol Biol Phys. 2005;63:449\u201355.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1882_CR16","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2967\/jnumed.107.046599","volume":"49","author":"J-P Garsi","year":"2008","unstructured":"Garsi J-P, Schlumberger M, Rubino C, Ricard M, Labb\u00e9 M, Ceccarelli C, et al. Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. J Nucl Med. 2008;49:845\u201352.","journal-title":"J Nucl Med"},{"key":"1882_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000468927","volume":"6","author":"NS Andresen","year":"2017","unstructured":"Andresen NS, Buatti JM, Tewfik HH, Pagedar NA, Anderson CM, Watkins JM. Radioiodine ablation following thyroidectomy for differentiated thyroid cancer: literature review of utility, dose, and toxicity. Eur Thyroid J. 2017;6:187\u201396.","journal-title":"Eur Thyroid J"},{"key":"1882_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/pmj.78.916.92","volume":"78","author":"L Vini","year":"2002","unstructured":"Vini L, Hyer S, Al-Saadi A, Platt B, Harmer C. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J. 2002;78:92\u20133.","journal-title":"Postgrad Med J"},{"key":"1882_CR19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/RLU.0000000000005570","volume":"50","author":"C-Y Lin","year":"2025","unstructured":"Lin C-Y, Lin C-L, Kao C-H. Risk of infertility in reproductive-age patients with thyroid cancer receiving or not receiving 131I treatment. Clin Nucl Med. 2025;50:201\u20137.","journal-title":"Clin Nucl Med"},{"key":"1882_CR20","first-page":"28S","volume":"46","author":"RJ Robbins","year":"2005","unstructured":"Robbins RJ, Schlumberger MJ. The evolving role of 131I for the treatment of differentiated thyroid cancer. J Nucl Med. 2005;46:28S-37S.","journal-title":"J Nucl Med"},{"key":"1882_CR21","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S0016-5085(24)05134-5","volume":"86","author":"RB Shafer","year":"1984","unstructured":"Shafer RB, Prentiss RA, Bond JH. Gastrointestinal transit in thyroid disease. Gastroenterology. 1984;86:852\u20135.","journal-title":"Gastroenterology"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-025-01882-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-025-01882-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-025-01882-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:35:24Z","timestamp":1769841324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-025-01882-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1882"],"URL":"https:\/\/doi.org\/10.1007\/s11604-025-01882-7","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests in this section.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of Ehime University Hospital (No. 2409004).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained by an opt-out form on the website.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}